Yuhan

000100 · KOSPI · ₩000100 · 유한양행

₩77,300▼ ₩2,700 (3.38%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me
News · Seoul Economic Daily·

Yuhan Operating Profit Up 51% on Lazertinib Royalties

Predicted impact: Medium

Operating profit up about 51% on royalties; preliminary Q3 earnings already reported in recent days.

News · Chosun Biz·

Yuhan and J&J's Lung Cancer Drug: Using Lazertinib First Reduces Skin Side Effects

Predicted impact: Low

Clinical sequencing finding on side effects for an existing partnered drug; no financial size given.

News · Edaily·

Yuhan Corp Expected to See Royalties on Lung Cancer Drug Jump 30% [Invest Bio]

Predicted impact: Medium

Royalty jump outlook is meaningful for Yuhan, but similar royalty and target news already covered in last 14 days.

News · Money Today·

Yuhan Corp Target Price Lowered from ₩160,000 to ₩110,000 on Valuation Method Change - IBK Securities

Predicted impact: Low· Actual: +4.0% vs sector, volume 2.7× normal (5 trading days)

Broker target cut from valuation method change; an earlier broker cut already covered in recent days

News · Yonhap News Agency·

IBK Securities Lowers Yuhan Target Price…"Q3 Results Expected to Meet Expectations"

Predicted impact: Low· Actual: +4.0% vs sector, volume 2.7× normal (5 trading days)

Target price cut with Q3 results in line with expectations; routine broker view.

News · Edaily·

Yuhan Corp: royalties from lung cancer drug soar…technology transfer of allergy treatment draws attention

Predicted impact: Medium· Actual: +4.0% vs sector, volume 2.7× normal (5 trading days)

Lazertinib sales above $300M quarterly; meaningful earnings driver, size vs revenue unclear.

News · The Korea Times·

Drugmaker Yuhan's historic headquarters wins Korea's top architectural honor

Predicted impact: Medium· Actual: +10.2% vs sector, volume 2.7× normal (5 trading days)

Lazertinib quarterly sales above $300M is meaningful, but already reported in the last 14 days.

News · Yonhap News Agency·

Yuhan's Lazertinib combination therapy sales surpass $300M for the first time

Predicted impact: Low· Actual: +10.2% vs sector, volume 2.7× normal (5 trading days)

Lazertinib combined sales above $300M were already reported in the past 14 days.

Also known as: Yuhan / 유한양행 / 000100 / KRX:000100

Source: KRX statistical information